Literature DB >> 15209464

The demonstration of serum interleukin 6-8, tumor necrosis factor-alpha, complement, and immunoglobulin levels in Behçet's disease with ocular involvement.

Yavuz Bardak1, Buket Cicioğlu Aridoğan.   

Abstract

PURPOSE: To investigate whether there are alterations in the humoral immune system in patients with Behçet's disease (BD) with ocular involvement.
METHODS: Twenty-four BD patients with active uveitis and without any other manifestations of the disease were included in Group I-a. The same patients were reassessed during the convalescence period and assigned to Group I-c. Moreover, 24 age- and sex-matched healthy controls (Group II) were included in the study. Serum levels of immunoglobulin (Ig) A, IgM, complement (C) 3, C4, interleukin (IL)-6, IL-8, and tumor necrosis factor-alpha (TNF-alpha) in Groups I-a, I-c, and II were measured and compared.
RESULTS: IgA, C3, C4, IL-6, IL-8, and TNF-alpha levels were higher in Group I-a than in Groups I-c and II.
CONCLUSIONS: IgA-, C3-, C4-, IL6-, IL8-, and TNF-alpha-mediated mechanisms might be responsible for ocular lesions in BD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15209464     DOI: 10.1076/ocii.12.1.53.28062

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  21 in total

1.  Visual aspects of Behçet's disease.

Authors:  Tulay Kansu; Sibel Kadayifcilar
Journal:  Curr Treat Options Neurol       Date:  2006-01       Impact factor: 3.598

Review 2.  The role of chemokines and their receptors in uveitis.

Authors:  Ahmed M Abu El-Asrar; Sofie Struyf; Ghislain Opdenakker; Karel Geboes; Jo Van Damme
Journal:  Int Ophthalmol       Date:  2007-03-13       Impact factor: 2.031

3.  Visfatin levels in Behcet's disease.

Authors:  Hatice Sezen; Seydi Okumus; Yavuz Pehlivan; Ismail Dilli; Mehmet Tarakcioğlu; Ahmet Mesut Onat
Journal:  Inflammation       Date:  2012-04       Impact factor: 4.092

4.  LPS-stimulated production of TNF-alpha by peripheral blood monocytes in patients with Behcet's disease.

Authors:  Gleb Slobodin; Yazeed Toukan; Itzhak Rosner; Michael Rozenbaum; Nina Boulman; Elsa Pavlotzky; Aharon Kessel; Elias Toubi
Journal:  Clin Rheumatol       Date:  2006-07-29       Impact factor: 2.980

Review 5.  Cytokines and chemokines in uveitis: is there a correlation with clinical phenotype?

Authors:  Kenneth G-J Ooi; Grazyna Galatowicz; Virginia L Calder; Susan L Lightman
Journal:  Clin Med Res       Date:  2006-12

6.  Anticardiolipin antibodies in patients with Behcet's disease.

Authors:  Maja Zivkovic; Marko Zlatanovic; Gordana Zlatanovic; Jasmina Djordjevic-Jocic; Sonja Cekic
Journal:  Bosn J Basic Med Sci       Date:  2011-02       Impact factor: 3.363

Review 7.  Visual aspects of Behçet's disease.

Authors:  Tulay Kansu; Sibel Kadayifcilar
Journal:  Curr Neurol Neurosci Rep       Date:  2005-09       Impact factor: 5.081

8.  Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet's disease.

Authors:  Ahmed M Abu El-Asrar; Emad B Abboud; Hassan Aldibhi; Abdulrahman Al-Arfaj
Journal:  Int Ophthalmol       Date:  2006-09-23       Impact factor: 2.031

Review 9.  Behçet syndrome: from pathogenesis to novel therapies.

Authors:  Gianluigi Mazzoccoli; Angela Matarangolo; Rosa Rubino; Michele Inglese; Angelo De Cata
Journal:  Clin Exp Med       Date:  2014-12-02       Impact factor: 3.984

10.  Lessons of the month 2: A case of Behçet's disease: 70% have ophthalmic involvement.

Authors:  Ishna Auluck; Ayesha Karimi; Simon Taylor
Journal:  Clin Med (Lond)       Date:  2019-11       Impact factor: 2.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.